Days after rapid FDA approval, Lilly and Blueprint go head-to-head again at ASCO
Eli Lilly may have gotten ahead of Blueprint with an approval last week, but it looks like the Big Pharma and the Cambridge biotech will be going toe-to-toe for a while.
In a pair of ASCO abstracts, both Lilly and Blueprint once again showed off positive data from their RET-inhibitors, setting up what could be a dual market for years to come. Analysts have been comparing the two drugs for years now, since before Lilly acquired their compound in the $8 billion Loxo buyout. Lilly got an edge with an FDA approval for its drug, called selpercatinib or Retevmo, last week — months ahead of the agency deadline — but Blueprint completed an NDA submission earlier this year and could be not far behind.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.